Liquid Biopsy for Guiding Treatment Decisions in Advanced Non-Small Cell Lung Cancer
1Guardant Health, Inc., Palo Alto, California, and University of Lynchburg, Lynchburg, Virginia.
Abstract:
Lung cancer is the leading cause of cancer-related deaths in the United States. The 5-year survival rates are poor with traditional therapy alone. New scientific advances in technology involving the human genome, including diagnostic tools to inform on tumor-derived acquired (somatic) mutations that drive cancer formation, are essential to utilize. Targeting cancer cells paired with actionable drugs to shut off growth pathways has significantly improved patient survival. Obtaining mutational analysis can be performed via traditional methods such as tissue; new advances allow comparable information obtained through liquid biopsy to inform targeted treatment decision-making. Getting tissue for additional molecular analysis can pose several challenges for patients. Liquid biopsy is a minimally invasive test (typically blood) analyzed by next-generation sequencing for tumor shed to obtain actionable information for treatment decisions. Analyses between blood and tissue consistently yield high concordance, with liquid biopsy providing faster turnaround time for results than tissue. The utility of liquid biopsy is well proven but not standardized and cannot diagnose lung cancer histopathology, which requires a tissue diagnosis.
Insights
Liquid biopsy, a blood test, offers a faster, less invasive way to analyze tumor mutations for lung cancer treatment. It shows high accuracy compared to tissue analysis, improving targeted therapy decisions.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Lung cancer remains a leading cause of cancer mortality in the US, with limited survival rates using traditional therapies alone.
- Advances in human genome technology, particularly identifying tumor-derived somatic mutations, are crucial for improving patient outcomes.
- Targeted therapies that block cancer growth pathways have significantly enhanced patient survival.
Purpose of the Study:
- To evaluate the utility of liquid biopsy as a diagnostic tool for identifying actionable mutations in lung cancer.
- To compare the effectiveness and efficiency of liquid biopsy against traditional tissue biopsy for molecular analysis.
- To highlight the role of liquid biopsy in informing targeted treatment decisions for lung cancer patients.
Main Methods:
- Utilizing next-generation sequencing (NGS) on liquid biopsy samples (blood) to detect tumor shed DNA.
- Comparing mutational analysis results from liquid biopsies with traditional tissue biopsies.
- Assessing turnaround times for molecular analysis between blood and tissue samples.
Main Results:
- Liquid biopsy provides comparable mutational information to tissue biopsy for treatment decision-making.
- Liquid biopsy demonstrates a faster turnaround time for results compared to tissue biopsy.
- High concordance rates were observed between liquid and tissue biopsy analyses.
Conclusions:
- Liquid biopsy is a valuable, minimally invasive tool for guiding targeted lung cancer therapy.
- While effective for molecular profiling, liquid biopsy cannot replace tissue diagnosis for lung cancer histopathology.
- Standardization of liquid biopsy protocols is necessary to optimize its clinical utility.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018